The White House Wants Veto Power Over Science Funding

It's not perfect, but it's designed so that scientific quality decides who gets money. The proposed executive order would bolt a new layer onto the end of that process, one where political appointees get the final word.

That's like letting a restaurant critic design the menu after the chef has already planned it.

This Didn't Come Out of Nowhere

The proposal is actually the latest escalation in a pattern that started in early 2025. That year, NIH was blocked from posting Federal Register notices, which stalled peer-review panels and delayed new grants. By mid-2025, the administration was reportedly requiring political review of funding decisions, and NIH leadership was told not to rely on peer-review scores as the final basis for awards.

In August 2025, an executive order gave political appointees formal authority over grants and instructed agencies not to "routinely defer" to expert review. By 2026, a proposed rule would treat peer review as advisory, not binding.

Each step pushed the same direction: less power for scientists, more power for the White House.

The Biotech World Is Not Taking This Quietly

The reaction from researchers, industry groups, and patient advocates has been swift and loud.

The Infectious Diseases Society of America warned that politicizing the process would have "far reaching consequences" for public health. PhRMA, the pharmaceutical industry's biggest trade group, said the proposal risks "undermining the very foundation" of U.S. biomedical research. BIO, which represents biotech companies, cautioned that uncertainty in research funding could drive talent and investment overseas.

Lawsuits have already been filed. Legal challengers argue the grant screening violates the First Amendment by adding an ideological review after grants have already passed scientific peer review. Stanford surgeon Arghavan Salles, one of the researchers named in a lawsuit, said scientists should not have to "scrub" their research to receive federal support.

The concern isn't hypothetical. Researchers report that words like "gender," "diversity," and "climate change" are already being flagged or avoided in grant applications. When the rules of the game become unclear, people stop playing.

Why Biotech Startups Should Be Paying Attention

If you're thinking "this is an academic problem, not a biotech problem," think again.

NIH-funded research is the soil that the entire biotech ecosystem grows from. University labs discover drug targets. Postdocs generate the data that becomes the founding intellectual property of startups. SBIR and STTR grants give early-stage companies non-dilutive capital before venture investors will touch them.

Political oversight introduces something startups can't afford: unpredictability. If founders can't plan multi-year programs around federal funding timelines, they burn cash faster, delay milestones, and struggle to raise. If universities green-light fewer projects because grant outcomes feel like a coin flip, fewer discoveries make it out of the lab and into company pipelines.

The effects won't show up tomorrow. They'll show up in three to five years, when the pipeline of new targets starts to thin. Fewer basic-science discoveries today means fewer drugs to develop later. It's a slow leak, not an explosion; the kind of problem that's easy to ignore until it's too late to fix.

The Bigger Question

America's dominance in biomedical research isn't an accident. It's the product of a system that, for all its flaws, has consistently separated scientific judgment from political pressure. NIH-funded research has contributed to virtually every major class of drugs on the market today.

The question this proposal raises isn't whether the government should have any say in how it spends $48 billion. Of course it should; that's what Congress does when it writes the budget. The question is whether two political appointees should be able to override the judgment of hundreds of scientific experts, grant by grant, based on whether the research fits a policy agenda.

The executive order hasn't been finalized yet. The White House hasn't publicly confirmed it. But the trajectory is clear, and the pattern of escalation over the past 18 months suggests this isn't just a trial balloon.

For anyone who cares about where the next generation of medicines comes from, this is the story to watch.

Sarepta's Worst Week Just Rewrote the Gene Therapy Playbook

Sarepta slapped a black box warning on its Duchenne gene therapy Elevidys and cut 36% of its workforce in one brutal announcement. The fallout raises hard questions about the commercial future of accelerated-approval gene therapies in rare disease.